Clinical Trial Update: A Trial to Assess the Lot Consistency, Safety, Tolerability and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Subjects Aged ≥10 to <19 Years [Phase 3]

View source ↗

Summary

A Phase 3 trial assessing lot consistency, safety, tolerability and immunogenicity of Pfizer's bivalent rLP2086 vaccine in healthy adolescents aged 10 to under …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningococcal Disease

Drugs mentioned

• Trumenba (rLP2086)

Snippet

Sponsor: Pfizer | Conditions: Meningococcal Vaccine | Phase 3 | Status: COMPLETED | Results posted: 2016-06-14